公开(公告)号：US20180251520A1

公开(公告)日：2018-09-06

申请号：US15984690

申请日：2018-05-21

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  G01N33/569 ,  A61K51/10 ,  C07K14/47 ,  C07K14/705 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12P21/02 ,  C12Q1/6881 ,  A61K39/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180251516A1

公开(公告)日：2018-09-06

申请号：US15965305

申请日：2018-04-27

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  C12Q1/6886 ,  A61K39/00 ,  C07K14/47 ,  C07K14/635 ,  C07K14/725 ,  C12N5/0783 ,  G01N33/574 ,  C07K16/28 ,  A61K38/00

CPC classification number: C07K14/70539 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  C07K14/4748 ,  C07K14/635 ,  C07K14/7051 ,  C07K16/2833 ,  C07K2319/70 ,  C12N5/0638 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57484

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180251507A1

公开(公告)日：2018-09-06

申请号：US15982397

申请日：2018-05-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Oliver SCHOOR ,  Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/47 ,  A61K39/00 ,  C07K16/30 ,  C07K14/74 ,  C07K16/28 ,  C12N5/0783 ,  C07K14/725 ,  C12N15/113

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180208640A1

公开(公告)日：2018-07-26

申请号：US15917159

申请日：2018-03-09

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  A61K38/08 ,  C07K16/30 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  C12N9/64 ,  G01N33/50 ,  G01N33/566 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/18 ,  C07K16/28 ,  A61K38/06 ,  G01N33/569 ,  C12Q1/6886 ,  A61K38/17

CPC classification number: C07K14/70539 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180207253A1

公开(公告)日：2018-07-26

申请号：US15918788

申请日：2018-03-12

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sara KUTSCHER

IPC: A61K39/00 ,  G01N33/68 ,  C07K14/725 ,  A61K38/04 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  A61K35/17 ,  C12N15/115 ,  C12N5/0783 ,  C07K16/18 ,  C07K14/74 ,  A61K35/12

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/04 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/5158 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/18 ,  C07K2317/70 ,  C07K2319/40 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12N2501/998 ,  G01N33/6803

Abstract: A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.

公开(公告)号：US20180064796A1

公开(公告)日：2018-03-08

申请号：US15799495

申请日：2017-10-31

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Colette SONG

IPC: A61K39/00 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C07K16/28 ,  G06F19/20 ,  C07K14/74 ,  C07K16/18 ,  C07K14/47 ,  A61K35/12 ,  C07K14/705

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K2035/124 ,  A61K2039/505 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/70539 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/3038 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/33 ,  C07K2319/55 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  G06F19/20

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170342125A1

公开(公告)日：2017-11-30

申请号：US15602746

申请日：2017-05-23

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  C07K7/06 ,  C07K7/08 ,  C07K14/725 ,  C12Q1/68 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  A61K39/00 ,  G01N33/50 ,  G01N33/574 ,  C07K16/28

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170305993A1

公开(公告)日：2017-10-26

申请号：US15638687

申请日：2017-06-30

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  C12Q1/68 ,  A61K45/06 ,  C12N5/0783 ,  C12N9/64 ,  C07K7/02 ,  C07K7/06 ,  C07K14/47 ,  C07K14/725 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  A61K38/08 ,  G01N33/566 ,  G01N33/569 ,  A61K39/00

CPC classification number: C07K14/70539 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：US20170305982A1

公开(公告)日：2017-10-26

申请号：US15638072

申请日：2017-06-29

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Phillip MUELLER ,  Julia LEIBOLD ,  Valentina GOLDFINGER

IPC: C07K14/47 ,  A61K39/00 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/574 ,  C12Q1/68 ,  C07K16/30 ,  A61K38/00

CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/30 ,  C07K2319/00 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57407 ,  G01N33/5748 ,  G01N33/6848 ,  G01N2570/00 ,  G01N2800/52

Abstract: A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.

公开(公告)号：US20170189513A1

公开(公告)日：2017-07-06

申请号：US15375058

申请日：2016-12-09

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K14/72 ,  C12N15/115 ,  C07K16/40 ,  C07K16/28 ,  C07K14/725 ,  C12N9/12 ,  C12N5/0783

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/71 ,  C07K14/721 ,  C07K14/8135 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/2869 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/0091 ,  C12N9/1264 ,  C12N15/115 ,  C12N2310/16 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Y116/01 ,  C12Y207/07031 ,  G01N33/57484 ,  G01N2333/47 ,  G06F19/20

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.